Maze Therapeutics director reports no MAZE share holdings

Maze Therapeutics, Inc. (MAZE) reported an initial statement of beneficial ownership for Paula A. Johnson, who is identified as a director.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) reported an initial statement of beneficial ownership for Paula A. Johnson, who is identified as a director. The filing lists no reportable transactions and no derivative positions, and the summary data shows no recorded share purchases, sales, or exercises at this time.

Key Figures

Buy transactions: 0 Sell transactions: 0 Derivative transactions: 0 +2 more

5 metrics

Buy transactions 0 Number of buy transactions reported in the Form 3 transaction summary

Sell transactions 0 Number of sell transactions reported in the Form 3 transaction summary

Derivative transactions 0 Derivative transaction count in the Form 3 transaction summary

Holding entries 0 Reported holding entries for non-derivative or derivative securities

Net buy/sell direction neutral Overall net buy/sell direction from the transaction summary

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"It represents Paula A. Johnson’s initial status as a reporting person"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"reported an initial statement of beneficial ownership for Paula A. Johnson"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"initial status as a reporting person for Maze Therapeutics"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for MAZE by Paula A. Johnson represent?

It represents Paula A. Johnson’s initial status as a reporting person for Maze Therapeutics, Inc. as a director. The filing establishes disclosure obligations going forward but currently reports no transactions or derivative positions.

Does the MAZE Form 3 for Paula A. Johnson show any share purchases or sales?

No. The summary shows 0 buy transactions and 0 sell transactions. The transactions section is empty, indicating no reportable purchases, sales, or other equity transactions included in this initial filing.

Are there any derivative securities reported for Paula A. Johnson in MAZE’s Form 3?

No. The filing’s derivative section is empty and the transaction summary reports 0 derivative transactions. This means no options, warrants, or other derivative positions are disclosed in this Form 3.

Is Paula A. Johnson reported as a 10% owner of MAZE in this Form 3?

No. The reporting-person data indicates she is a director and not a 10% owner. Her role triggers reporting requirements, but the form does not categorize her as holding 10% or more of MAZE’s stock.

Does the MAZE Form 3 mention any Rule 10b5-1 trading plan for Paula A. Johnson?

No. The document-level indicator for Rule 10b5-1 status is null, and there are no transaction footnotes describing a trading plan. With no transactions reported, there is no plan-related timing information here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/17/2026 - 04:45 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Johnson Paula A

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/13/2026

3. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Courtney Phillips, as attorney-in-fact	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)